Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2009
10/01/2009WO2009118974A1 Administration method proposing device
10/01/2009WO2009118749A1 Benzophenone-piperazine linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids as potential anticancer agents and process for the preparation thereof
10/01/2009WO2009118748A1 Isoxazoline linked pyrrolo[2,1-c[1,4]benzodiazepine hybrids as potential anticancer agents and the process for preparation thereof
10/01/2009WO2009118567A2 Pyrimidines, triazines and their use as pharmaceutical agents
10/01/2009WO2009118560A1 Combination therapy 038
10/01/2009WO2009118475A2 Platinum-n-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof
10/01/2009WO2009118473A2 Azetidine-derived compounds, preparation method therefor and therapeutic use of same
10/01/2009WO2009118443A1 Oviedomycin derivatives, method for obtaining same and use thereof
10/01/2009WO2009118384A1 Quinazolinone derivatives as tubulin polymerization inhibitors
10/01/2009WO2009118382A1 Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors
10/01/2009WO2009118370A1 Aza-bicyclohexyl substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
10/01/2009WO2009118305A1 Hydroxamate-based inhibitors of deacetylases b
10/01/2009WO2009118142A1 Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin' s lymphomas
10/01/2009WO2009117985A1 Pirinixic acid derivatives as prostglandin e2 synthesis inhibitors for treating inflammatory diseases
10/01/2009WO2009117902A1 5-demethoxyfumagillol and derivatives thereof
10/01/2009WO2009117899A1 The polymorphs of 4-anilinoquinazoline derivatives, the preparation methods and uses thereof
10/01/2009WO2009117831A1 Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
10/01/2009WO2009117828A1 Saponin extract from saponaria spp. and uses thereof
10/01/2009WO2009117804A1 An anti-cancer cytotoxic monoclonal antibody
10/01/2009WO2009117769A1 Inhibition of c-kit cancers
10/01/2009WO2009100011A3 Targeted cellular selectivity of surface active molecules
10/01/2009WO2009095399A3 Pyrazine derivatives and their use as protein kinase inhbitors
10/01/2009WO2009093253A3 Compositions and methods for modulating vascular endothelial growth factor c (vegf-c) expression
10/01/2009WO2009090240A3 Use of factor viia or factor viia equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ich) in a selected subpopulation of ich patients
10/01/2009WO2009079797A9 Compounds and method for treatment of cancer
10/01/2009WO2009079767A9 Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer
10/01/2009WO2009074300A3 Hedgehog pathway antagonists and therapeutic applications thereof
10/01/2009WO2009073050A3 Use of curcumin to block brain tumor formation in vivo
10/01/2009WO2009060835A8 Novel ubiquilin-binding small molecule
10/01/2009WO2009047216A3 Use of indolocarbazole imides as protein kinase inhibitors for the treatment of hematologic and solid tumors
10/01/2009WO2009033809A3 Use of a peptide as a therapeutic agent
10/01/2009WO2009033730A3 Peptide gxgrgdspca as a therapeutic agent
10/01/2009WO2009033666A3 Use of parathyroid hormone ( 1-34 ) as anti-hiv agent
10/01/2009US20090249502 Exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in cancers; provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer; antibody or antigen-binding fragment thereof that specifically binds to a 193P1E1B protein; drug delivery
10/01/2009US20090249500 System for monitoring bacterial tumor treatment
10/01/2009US20090248316 Method for supporting a diagnosis of an effect of a treatment by using anthracycline anticancer drugs and a device for supporting a diagnosis for an effect of a treatment by using anthracycline anticancer drugs
10/01/2009US20090247741 Process for the production of multiple cross-linked hyaluronic acid derivatives
10/01/2009US20090247731 Boronic ester and acid compounds, synthesis and uses
10/01/2009US20090247647 Method of Stimulating Proteoglycan Synthesis in Cells
10/01/2009US20090247641 Hydrazone agents to treat cutaneous lesions
10/01/2009US20090247613 Chemically synthesized nucleic acid molecule with a pyrimidine modification; cancer, ocular disease, and other proliferative disorders; neovascularization, diabetic retinopathy, restenosis and polycystic kidney disease
10/01/2009US20090247611 Method of treating a cancer with a survivin antisense oligonucleotide and paclitaxel
10/01/2009US20090247606 RNA Interference Mediated Inhibition of Adenosine A1 Receptor (ADORA1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
10/01/2009US20090247599 Methods of treating cell proliferative disorders using a compressed temozolomide dosing schedule
10/01/2009US20090247598 Treatment methods
10/01/2009US20090247592 Epothilones C, D, E, and F, Preparation and Compositions
10/01/2009US20090247590 Indane amides
10/01/2009US20090247576 Anti-tumor agent for multiple myeloma
10/01/2009US20090247565 receptor tyrosine kinase MET inhibitors; anticancer agents; 8-phenyl-10H-furo[2',3':4,5]cyclohepta[1,2-b]pyridin-10-one
10/01/2009US20090247559 Benzofuropyrimidinones
10/01/2009US20090247554 Kinase inhibitors
10/01/2009US20090247549 Methods of using saha and bortezomib for treating cancer
10/01/2009US20090247547 Hydroxamate-based inhibitors of deacetylases b
10/01/2009US20090247540 Peptide and small molecule agonists of epha and their uses
10/01/2009US20090247533 Ecteinascidins
10/01/2009US20090247524 HSP90 Inhibitor
10/01/2009US20090247522 Hsp90 FAMILY PROTEIN INHIBITORS
10/01/2009US20090247518 6-(2-alkyl-phenyl)-pyrido[2,3-d]pyrimidines useful as protein kinase inhibitors
10/01/2009US20090247507 Enzyme Inhibitors
10/01/2009US20090247501 Protein kinase inhibitors
10/01/2009US20090247497 Formulation and use of ergosta-7,22-dien-3beta-ol
10/01/2009US20090247495 Cucurbitacin b and uses thereof
10/01/2009US20090247492 Manganese based organometallic complexes, pharmaceutical compositions and dietetic products
10/01/2009US20090247491 Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof
10/01/2009US20090247487 Combination Therapy to Treat Hepatitis B Virus
10/01/2009US20090247480 Anti-cancer therapies
10/01/2009US20090247477 Methods of suppressing uv light-induced skin carcinogenesis
10/01/2009US20090247472 Type 1, 4-naphtoquinone compounds, compositions comprising them and use of these compounds as anti-cancer agents
10/01/2009US20090247467 Peptide epitopes of vegfr-2/kdr that inhibit angiogenesis
10/01/2009US20090247456 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
10/01/2009US20090246855 Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
10/01/2009US20090246793 Cudr as biomarker for cancer progression and therapeutic response
10/01/2009US20090246291 Method and compositions for treatment of cancer
10/01/2009US20090246274 Pharmaceutical composition 271
10/01/2009US20090246272 Mda-7 proteins and methods of use thereof
10/01/2009US20090246268 Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors
10/01/2009US20090246216 Novel attenuated poliovirus
10/01/2009US20090246211 Molecular constructs suitable for targeted conjugates
10/01/2009US20090246205 Inhibition of macrophage-stimulating protein receptor (ron)
10/01/2009US20090246202 Human Endokine Alpha and Methods of Use
10/01/2009US20090246201 Substances
10/01/2009US20090246198 Mapk/erk kinase inhibitors and methods of use thereof
10/01/2009US20090246197 Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc)
10/01/2009US20090246194 ERYTHROPOIETIN ANALOG-IgG FUSION PROTEINS
10/01/2009US20090246188 Method for Production of a Bioengineered Form of Tissue Plasminogen Activator
10/01/2009US20090246173 Treatment with anti-vegf antibodies
10/01/2009US20090246172 Compositions comprising epothilones and their use for the treatment of carcinoid syndrome
10/01/2009US20090246169 Indolopyridines as eg5 kinesin modulators
10/01/2009US20090246168 Antitumoral treatments
10/01/2009US20090246167 Stimuli-responsive systems for controlled drug delivery
10/01/2009US20090246133 Methods and compositions related to internalizing rgd peptides
10/01/2009US20090246132 Epitope bound by MAbs A, B, C or D, where MAbs A, B, C and D have given variable domains; chimeric or humanized for side effect reduction; polymerase chain reaction
10/01/2009US20090246130 Methods and Compositions for F-18 Labeling of Proteins, Peptides and Other Molecules
10/01/2009US20090246129 Compositions and methods for the diagnosis and treatment of tumor
10/01/2009US20090246128 Composition and method for detection of pre-metastatic sites
10/01/2009US20090246124 High affinity vegf-receptor antagonists
10/01/2009CA2756731A1 Compositions and methods for diagnosing and treating melanoma
10/01/2009CA2719766A1 Method and compositions for treatment of cancer
10/01/2009CA2719555A1 Saponin extract from saponaria spp. and uses thereof
10/01/2009CA2719544A1 Novel substituted imidazoquinolines
1 ... 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 ... 2211